Trimethobenzamide: Difference between revisions
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antiemetic | *Type: [[Antiemetic]] | ||
*Dosage Forms: 200mg, 300mg | *Dosage Forms: 200mg, 300mg | ||
*Routes of Administration: IM, PO | *Routes of Administration: IM, PO | ||
| Line 50: | Line 50: | ||
==Comments== | ==Comments== | ||
No known QTc prolonging effects | *No known QTc prolonging effects | ||
==See Also== | ==See Also== | ||
Latest revision as of 15:02, 10 May 2023
Administration
- Type: Antiemetic
- Dosage Forms: 200mg, 300mg
- Routes of Administration: IM, PO
- Common Trade Names: Tigan
Adult Dosing
Nausea/Vomiting
- 200mg IM q8h prn, 300mg PO q8h prn
- Can be used as an antiemetic in patients with a prolonged QTc
Pediatric Dosing
Nausea/Vomiting
- Expert recommendations do not suggest trimethobenzamide as a therapeutic option; use has been replaced by newer agents with an improved safety profile
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Hypersensitivity to trimethobenzamide or any component of the formulation
- Use in pediatric patients (injection only)
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 7 to 9 hours
- Metabolism: Via oxidation, forms metabolite trimethobenzamide N-oxide
- Excretion: Urine (30% to 50%, as unchanged drug)
Mechanism of Action
- Acts centrally to inhibit the medullary chemoreceptor trigger zone by blocking emetic impulses to the vomiting center
Comments
- No known QTc prolonging effects